Last checked at 7 Nov 2023 08:10
THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN REDX PHARMA PLC IN ANY JURISDICTION.
THE SECURITIES DISCUSSED HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. ADDITIONALLY, THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER SECURITIES COMMISSION OR REGULATORY AUTHORITY IN THE UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THE SUBSCRIPTION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
REDX PHARMA PLC
("Redx" or "the Company")
Admission of Subscription Shares and Total Voting Rights
Alderley Park, 7 November 2023, Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer, announces that the admission to trading on AIM of the 54,074,458 Subscription Shares referred to in the announcement of the Results of General Meeting on 6 November 2023 became effective at 8:00 a.m. this morning.
Key highlights
· Subscription for 54,074,458 Subscription Shares at the Issue Price of 26 pence per Subscription Share to raise £14,059,359 (before expenses) by existing shareholders.
· One of the Redmile Funds, which taken together are the Company's largest shareholder, has participated in the Subscription and has subscribed for 31,548,692 Subscription Shares at the Issue Price. Sofinnova Partners, an existing Shareholder, has also participated in the Subscription and has subscribed for 7,887,173 Subscription Shares at the Issue Price. In addition, Polar Capital and Invus, both existing shareholders of the Company, have also participated in the Subscription, either directly or through entities in their respective groups.
Following Admission, the number of Ordinary Shares in issue and the number of total voting rights will be 388,985,916. The figure of 388,985,916 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined herein shall have the same meanings given to them in the announcement of the Subscription by the Company on 18 October 2023.
The person responsible for the release of this announcement on behalf of the Company is Nischal Hindia, Interim General Counsel & Company Secretary.
For further information, please contact: |
|
|
|
Redx Pharma plc Caitlin Pearson, Head of Communications ir@redxpharma.com
UK Headquarters Lisa Anson, Chief Executive Officer
| T: +44 (0)1625 469 918 |
US Office Peter Collum, Chief Financial Officer | |
| |
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
Matt Davis/ Adam Dawes
MTS Securities, LLC (Exclusive Placement Agent) |
T: +1 212 887 2100 |
Mark Epstein | |
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
Claes Spång/ Satheesh Nadarajah/ David Wilson | |
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
Rupert Dearden/ Freddy Crossley/ Emma Earl | |
FTI Consulting | T: +44 (0)203 727 1000 |
Simon Conway/ Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application during the fourth quarter of 2023. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development. In October 2023, Redx nominated its next development candidate, RXC009 a highly potent and selective DDR1 inhibitor for the treatment of chronic kidney disease and associated fibrosis.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.